Sglt2 Inhibitor

Patients with type 2 diabetes who receive sodium-glucose transport protein 2 inhibitors may have a lower risk for gout compared with those using dipeptidyl peptidase 4 inhibitors, according to data published in JAMA Network Open.

The initiation of SGLT-2 inhibitors correlated with a reduced risk of AKI in older adults with type 2 diabetes compared with other glucose-lowering medications.

In this video, Nancy K. Sweitzer, MD, PhD, director of the University of Arizona Sarver Heart Center and professor of medicine and chief of the division of cardiology at the University of Arizona College of Medicine, Tucson, discusses the types of research presented on HF at this year’s American Heart Association Scientific Sessions.

The kidney community is in a sweet spot with the availability of new and effective therapies that prevent the progression of both diabetic and non-diabetic kidney diseases.

Clinicians should be cautious when prescribing certain antihyperglycemic agents for people with type 2 diabetes at risk for fracture, particularly when a patient is older with long disease duration or complications, according to a speaker.

A novel risk calculator leveraging two widely available clinical biomarkers can accurately predict heart failure hospitalization for adults with type 2 diabetes at high atherosclerotic cardiovascular disease risk, data show.

The nonsteroidal mineralocorticoid receptor antagonist finerenone provides cardiovascular and kidney benefits in adults with diabetic kidney disease independent of and combined with SGLT2 inhibitors, new analyses show.

WHO has updated its Model Lists of Essential Medicines and Essential Medicines for Children, adding 20 medicines for adults and 17 for children in addition to new uses for 28 previously listed medicines.

Multiple pathophysiologic abnormalities contribute the development and progression of diabetic kidney disease, and early intervention with triple or even quadruple therapy is needed to prevent complications, according to a speaker.

SGLT2 inhibitors may directly or indirectly impact factors associated with diabetes and atrial fibrillation/atrial flutter, according to a speaker at the Heart in Diabetes CME Conference.